Nuformix to investigate a new formulation of NXP002
Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has provided an update in relation to the Company’s NXP002 asset, a new form of